News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Mela Sciences (MELA) to Host Investor Meeting May 7, 2012 in New York


4/23/2012 10:09:25 AM

IRVINGTON, NY--(Marketwire - April 23, 2012) - MELA Sciences, Inc. (NASDAQ: MELA), the medical device company that has developed MelaFind®, today announced that it will host a meeting for investors and analysts on Monday, May 7, 2012, 10-11 AM ET in New York City.

Joseph V. Gulfo, MD, MELA Sciences President and CEO, will host the meeting and provide a brief introduction and business update. He will then moderate a panel discussion and presentations from leading dermatologists. The clinicians will discuss their current practice patterns, the clinical utility of MelaFind and how they are incorporating it into their practice as well as the product's potential market opportunity. Following the presentations, there will be a question and answer session.

Space is limited, those interested in attending should RSVP to Lynn Pieper at lynn.pieper@westwicke.com.

A live audio webcast and slides of the MELA Sciences Investor Meeting will be accessible through the investor relations section of the Company's website at www.melasciences.com. An archived edition of the presentation will be available later that day and will be available for at least 90 days afterwards.

About MELA Sciences, Inc.
MELA Sciences is a medical device company focused on the commercialization of its flagship product, MelaFind®, and its further design and development. MelaFind is a non-invasive tool to provide additional information to dermatologists during melanoma skin examinations. The device uses light from visible to near-infrared wavelengths to evaluate skin lesions up to 2.5 mm beneath the skin. The device provides information on a lesion's level of morphologic disorganization to provide additional objective information that may be used by dermatologists in the biopsy decision-making process. MelaFind has been approved by the US Food and Drug Administration for use in the US. In addition, MelaFind has received CE Mark approval and is approved for use in the European Union.

For more information on MELA Sciences, visit www.melasciences.com.


For further information contact:

For Investors
Lynn Pieper
Westwicke Partners
415-202-5678

For Media
Melissa Hurley
Ricochet Public Relations
212-679-3300 x128


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES